• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性硬皮病患者肺动脉高压的发生率及相关影响因素。

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.

机构信息

Cardiology Dept, Royal Free Hospital, London, UK.

Both authors contributed equally.

出版信息

Eur Respir J. 2018 Apr 4;51(4). doi: 10.1183/13993003.01197-2017. Print 2018 Apr.

DOI:10.1183/13993003.01197-2017
PMID:29563168
Abstract

The objective of this study was to evaluate the incidence of pulmonary hypertension (PH) and determining factors in patients with systemic sclerosis (SSc) and a diffusing capacity of the lung for carbon monoxide () <60% predicted.In this bicentric, prospective cohort study, patients with SSc were clinically assessed at baseline and after 3 years, including right heart catheterisation (RHC). Analysis of determining factors for the development of PH was performed using univariate and multivariate analyses.96 patients with a mean pulmonary arterial pressure (mPAP) <25 mmHg at baseline were followed for 2.95±0.7 years (median 3 years). Of these, 71 had a second RHC; 18 of these 71 patients (25.3%) developed PH, and five (7%) developed SSc-associated pulmonary arterial hypertension. For patients with an mPAP of 21-24 mmHg at baseline, the likelihood of presenting with PH as opposed to normal pressures on follow-up was significantly higher (p=0.026). Pulmonary vascular resistance, tricuspid regurgitation velocity, diffusion capacity and the size of the inferior vena cava at baseline were independent predictors for the development of PH during follow-up.In a selected cohort of SSc patients with a <60%, pulmonary pressures appeared to rise progressively during follow-up. In this population, it was possible to identify manifest PH in almost 25% of patients using prospective RHC during follow-up. Therefore, regular clinical assessment including RHC might be useful in patients with SSc.

摘要

本研究旨在评估系统性硬化症(SSc)患者中肺动脉高压(PH)的发生率及其影响因素,这些患者的一氧化碳弥散量(DLCO)<60%预计值。

在这项双中心前瞻性队列研究中,在基线和 3 年后对 SSc 患者进行临床评估,包括右心导管检查(RHC)。采用单变量和多变量分析来分析 PH 发展的决定因素。

96 例基线平均肺动脉压(mPAP)<25mmHg 的患者平均随访 2.95±0.7 年(中位数 3 年)。其中,71 例患者进行了第二次 RHC;71 例患者中有 18 例(25.3%)出现 PH,5 例(7%)出现与 SSc 相关的肺动脉高压。对于基线 mPAP 为 21-24mmHg 的患者,与随访时正常压力相比,出现 PH 的可能性明显更高(p=0.026)。基线时的肺血管阻力、三尖瓣反流速度、弥散能力和下腔静脉大小是随访期间 PH 发生的独立预测因素。

在一个 DLCO<60%的 SSc 患者亚组中,在随访期间,肺压似乎逐渐升高。在这一人群中,通过前瞻性 RHC 在随访期间可发现近 25%的患者存在明显 PH。因此,定期进行包括 RHC 的临床评估可能对 SSc 患者有益。

相似文献

1
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.系统性硬皮病患者肺动脉高压的发生率及相关影响因素。
Eur Respir J. 2018 Apr 4;51(4). doi: 10.1183/13993003.01197-2017. Print 2018 Apr.
2
Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.一氧化碳弥散量降低可预测系统性硬化症患者的肺动脉压处于临界值。
Rheumatol Int. 2019 Nov;39(11):1883-1887. doi: 10.1007/s00296-019-04370-0. Epub 2019 Jul 6.
3
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.特发性肺动脉高压患者血流动力学正常与边缘平均肺动脉压患者的基线特征及随访:PHAROS 注册研究结果。
Ann Rheum Dis. 2012 Aug;71(8):1335-42. doi: 10.1136/annrheumdis-2011-200546. Epub 2012 Feb 2.
4
Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.利用肺功能测试提高系统性硬化症中肺动脉高压的检测率。
Arthritis Rheum. 2011 Nov;63(11):3531-9. doi: 10.1002/art.30535.
5
Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.弥散量一氧化碳与超声心动图参数在 EUSTAR 系统性硬化症患者队列中识别轻度肺动脉高压的比较。
Chest. 2024 Oct;166(4):837-844. doi: 10.1016/j.chest.2024.05.010. Epub 2024 Jun 6.
6
Determining the necessity for right heart catheterization in pulmonary hypertension associated with connective tissue diseases assessed by echocardiography.通过超声心动图评估结缔组织病相关肺动脉高压时确定右心导管检查的必要性。
Int J Rheum Dis. 2016 Jan;19(1):65-73. doi: 10.1111/1756-185X.12769. Epub 2015 Oct 7.
7
Combination of echocardiography and pulmonary function tests could predict no complication of pulmonary hypertension during 5 years in patients with systemic sclerosis.超声心动图和肺功能测试的联合应用可预测系统性硬化症患者 5 年内肺动脉高压无并发症。
Int J Rheum Dis. 2023 Mar;26(3):493-500. doi: 10.1111/1756-185X.14576. Epub 2023 Feb 3.
8
Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.特发性和系统性硬化症相关肺动脉高压:人口统计学、血流动力学和 MRI 特征及预后的比较。
Chest. 2017 Jul;152(1):92-102. doi: 10.1016/j.chest.2017.02.010. Epub 2017 Feb 20.
9
Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.系统性硬化症相关肺动脉高压:系统性筛查诊断和 3 年随访预后。
BMC Pulm Med. 2021 Jul 29;21(1):251. doi: 10.1186/s12890-021-01618-z.
10
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.高N末端脑钠肽前体水平和低一氧化碳弥散能力作为系统性硬化症患者毛细血管前肺动脉高压发生的独立预测因素。
Arthritis Rheum. 2008 Jan;58(1):284-91. doi: 10.1002/art.23187.

引用本文的文献

1
Bridging knowledge gaps: A case report of pulmonary Veno-occlusive disease in systemic sclerosis.弥合知识差距:系统性硬化症合并肺静脉闭塞病的病例报告
Lung India. 2025 May 1;42(3):248-251. doi: 10.4103/lungindia.lungindia_481_24. Epub 2025 Apr 29.
2
Shifting Paradigms in the Management of Pulmonary Hypertension.肺动脉高压管理中的范式转变
Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. eCollection 2024.
3
The latest definition and classification of pulmonary hypertension.肺动脉高压的最新定义和分类。
Int J Cardiol Congenit Heart Dis. 2024 Jul 31;17:100534. doi: 10.1016/j.ijcchd.2024.100534. eCollection 2024 Sep.
4
Prevalence of pulmonary hypertension and its associated factors among chronic obstructive pulmonary diseases patients at public hospitals of Addis Ababa, Ethiopia, 2024: a facility-based cross-sectional study.2024年埃塞俄比亚亚的斯亚贝巴公立医院慢性阻塞性肺疾病患者肺动脉高压的患病率及其相关因素:一项基于机构的横断面研究
Front Public Health. 2024 Nov 26;12:1456235. doi: 10.3389/fpubh.2024.1456235. eCollection 2024.
5
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.系统性硬化症及其器官表现的流行病学范围综述:2018 - 2024年
Curr Opin Rheumatol. 2025 Mar 1;37(2):103-112. doi: 10.1097/BOR.0000000000001063. Epub 2024 Oct 23.
6
Towards a Better Prognosis in Patients with Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Recent Developments and Perspectives.改善系统性硬化症相关肺动脉高压患者的预后:最新进展与展望
J Clin Med. 2024 Sep 30;13(19):5834. doi: 10.3390/jcm13195834.
7
Exercise pulmonary hypertension in patients with systemic sclerosis based on updated guidelines.根据更新的指南,对系统性硬皮病患者进行运动性肺动脉高压检查。
Sci Rep. 2024 Jun 11;14(1):13358. doi: 10.1038/s41598-024-63823-0.
8
The Management of Mild Pulmonary Hypertension in Clinical Practice.临床实践中的轻度肺动脉高压管理。
Ann Am Thorac Soc. 2024 Aug;21(8):1115-1123. doi: 10.1513/AnnalsATS.202312-1079FR.
9
Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications.肺动脉高压的更新临床分类、血流动力学定义及其临床意义
J Cardiovasc Dev Dis. 2024 Feb 27;11(3):78. doi: 10.3390/jcdd11030078.
10
Endothelial cell clonality, heterogeneity and dysfunction in pulmonary arterial hypertension.肺动脉高压中的内皮细胞克隆性、异质性及功能障碍
Front Med (Lausanne). 2023 Dec 6;10:1304766. doi: 10.3389/fmed.2023.1304766. eCollection 2023.